Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-benzylidenenaltrexone
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
7-Benzylidenenaltrexone (BNTX) is a small-molecule research compound and a selective delta-1 opioid receptor (DOR1) antagonist. It is a morphinan derivative of naltrexone, synthesized via the aldol condensation of naltrexone with benzaldehyde. BNTX exhibits high affinity for the delta-1 opioid receptor (Ki = 0.1 nM) with significantly lower affinity for the delta-2, mu, and kappa opioid receptors. It is widely utilized as a pharmacological tool in preclinical research to study opioid receptor subtypes, antinociception, and cardioprotection. Additionally, BNTX has demonstrated preclinical activity as a DOR1-independent immunosuppressant, reducing autoreactive B cells and improving lupus nephritis in mouse models, as well as reversing chloroquine resistance in Plasmodium chabaudi.
- Other names
- 7-benzylidenenaltrexone maleate7(E)-BenzylidenenaltrexoneBNTX maleate
02
Targets
DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on 7-benzylidenenaltrexone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7-benzylidenenaltrexone.